After having experienced some movement in the previous week, the Northwest Biotherapeutics (OTCMKTS:NWBO) stock has been trading within a narrow range over the past few days.
There has been no news regarding the company in recent days but back on May 12 there was a major development. On that day, the company announced that it submitted an application to the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom for certifying its manufacturing facility in Sawston.
This is a considerable milestone for the company since Northwest Biotherapeutics had prepared for this application for as long as two years. As a matter of fact, the bulk of the preparation had taken place at the time when the United Kingdom was reeling from the effects of the coronavirus pandemic. Back on March 16 this year, it had been reported that the physical build out of the facility had been completed as part of these preparations.
|CCI20||60.2181||Buy||Chaikin Money Flow||0.1067||Buy|
|MACD||0.0541||Buy||Money Flow Index||58.1632||Sell|
|STOCH (14,3)||38.8356||Sell||STOCH RSI||1.0000||OverBought|